Osimertinib granted accelerated FDA approval for lung cancer treatment.
+ Technology/Innovation
Jamie Barrand | Nov 16, 2015

Osimertinib granted accelerated FDA approval for lung cancer treatment

Osimertinib (TAGRISSO), a once-daily tablet indicated for the treatment of specific lung cancers, has been granted accelerated approval by the U.S. Food and Drug Administration (FDA).

Osimertinib, a product of AstraZeneca Pharmaceuticals LP, can be used to treat patients who have had a positive, FDA-approved test for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

Additionally, patients must have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy in order to qualify for the treatment.

Organizations in this story

More News